America Biopharmaceutical Company Vertex Pharmaceuticals Shares Crashes

American Biopharmaceutical Company Vertex Pharmaceuticals Inc. shares slumped 0.53% to $196.78 Tuesday. This proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.03% to 4,291.80 and the Dow Jones Industrial Average DJIA rising 0.03% to 34,292.29.

 Vertex Pharmaceuticals Inc. closed $109.30 below its 52-week high ($306.08), which the company reached on July 7th. The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson JNJ rose 0.01% to $164.03, Merck & Co. Inc. MRK rose 0.46% to $77.21, and AbbVie Inc. ABBV fell 0.62% to $112.30.

Vertex Pharmaceuticals Inc trading volume (2.6 M) eclipsed its 50-day average volume of 2.1 M.The stock’s fall snapped a three-day winning streak.Coming into today, shares of the drugmaker had lost 6.85% in the past month. In that same time, the Medical sector gained 3.46%, while the S&P 500 gained 2.34%.Wall Street will be looking for positivity from VRTX as it approaches its next earnings report date.

On that day, VRTX is projected to report earnings of $2.73 per share, which would represent year-over-year growth of 4.6%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.72 billion, up 12.54% from the year-ago period.Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $11.22 per share and revenue of $6.92 billion. These totals would mark changes of +8.72% and +11.44%, respectively, from last year.